Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 19, 2023Journal of Cancer Research and Clinical OncologyOpen Access

A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAnna FleischerUniversitätsklinikum WürzburgLZLarissa ZapfJAJohannes AllgaierUniversity of Würzburg

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Fleischer et al. (2023) studied this question.

synapsesocial.com/papers/6ab0eae097a3794889ec4f18https://doi.org/10.1007/s00432-023-05137-8
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany2020 · 57 citations
  2. 2Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis2017 · 693 citations
  3. 3Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment2014 · 66 citations
  4. 4Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study2013 · 133 citations
  5. 5Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States2022 · 15 citations